Reduction of menopausal hot flushes by methyldopa. A double blind crossover trial

Eur J Clin Pharmacol. 1981;20(6):413-6. doi: 10.1007/BF00542092.


In a double-blind study, methyldopa was shown to be significantly more effective than placebo in reducing menopausal hot flushes. The median reduction in the number of hot flushes was 38% with placebo and 65% with methyldopa. The active metabolite of methyldopa, alpha-methylnoradrenaline, is an alpha 2-adrenoceptor agonist. Since the alpha 2-adrenoceptor agonist clonidine also reduces hot flushes, while the alpha 2-adrenoceptor antagonist yohimbine produces flushes, it is speculated that menopausal hot flushes might result from a reduced stimulation of alpha 2-adrenoceptors, probably in the CNS.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Climacteric / drug effects*
  • Clinical Trials as Topic
  • Double-Blind Method
  • Female
  • Humans
  • Methyldopa / adverse effects
  • Methyldopa / pharmacology*
  • Placebos


  • Placebos
  • Methyldopa